The global Dry Age-Related Macular Degeneration market reached USD 5.3 billion in 2026 and is projected to reach USD 14.9 billion by 2040, growing at a CAGR of 7.66% over the forecast period 2026 to 2040, driven by geographic atrophy therapy uptake, PBM adoption, and AI monitoring. Based on Geography, North America captures 42.0% market share in 2026, whereas Asia-Pacific registers a 9.8% CAGR through 2040, supported by Japan and China access expansion. Approved GA therapies now pull revenue tow...

The global insulin pump market, valued at USD 6.1 billion in 2025, is projected to reach USD 6.5 billion in 2026 and USD 13.6 billion by 2035, representing a CAGR of 8.5% during the forecast period 2026 to 2035. In terms of type of pump, the patch pumps segment holds the highest (more than 60%) share of the current market. The emergence of automated insulin delivery systems represents a defining shift in the domain. These platforms use real-time glucose data and algorithms to adjust insulin deli...

The global plant-based meat market, valued at USD 18.7 billion in 2025, is projected to reach USD 20.6 billion in 2026 and USD 54.8 billion by 2035, representing a CAGR of 11.5% during the forecast period 2026 to 2035. In terms of source of protein, soy protein holds the largest share, accounting for approximately 45% of the current plant-based meat market.

The global inflammatory bowel disease treatment market size, valued at USD 22.6 billion in 2025, is projected to reach USD 24.3 billion in 2026 and USD 43.8 billion by 2035, representing a CAGR of 6.8% during the forecast period 2026 to 2035. Close to 30 drugs are currently approved for the treatment of inflammatory bowel disease. However, these drugs often fail to achieve sustained remission in a significant subset of patients and frequently lose effectiveness over time. Many drugs are associat...

The global antibody drug conjugate market, valued at USD 15.29 billion in 2025, is projected to reach USD 18.69 billion in 2026 and USD 28.41 billion by 2035, representing a CAGR of 4.8% from 2026 to 2035. Breast Cancer therapies currently account for 44.7% of the antibody drug conjugate (ADC) market, supported by the large treated population, established HER-2-targeted products, and sustained development. The lung cancer segment will likely grow at a higher CAGR and occupy a larger market share...

The global ADC contract manufacturing market, valued at USD 1,720 million in 2025, is projected to reach USD 2,138 million in 2026 and USD 3,212 million by 2035, representing a CAGR of 4.6% during the forecast period. An expanding oncology pipeline of over 600 ADC candidates and 28 approved ADC therapeutic programs is increasing demand for outsourced bioconjugation, cGMP manufacturing, high-potency handling, and commercial-scale supply. Antibody manufacturing dominates the current market by proc...

The global antibody discovery market, valued at $2.0 billion in 2025, is projected to reach $2.2 billion in 2026 and $6.3 billion by 2035, representing a CAGR of 12.3% during the forecast period 2026 to 2035. This market includes the opportunity for antibody discovery service and technologies / platform providers across the full discovery workflow, from target identification and hit generation through lead selection, lead optimization, and preclinical validation. Oncological disorders account fo...

The global lipid nanoparticle manufacturing market, valued at USD 0.35 billion in 2025, is projected to reach USD 0.38 billion in 2026 and USD 2.53 billion by 2035, representing a CAGR of 23.4% during the forecast period 2026 to 2035. In terms of key geographical regions, North America holds the largest share, capturing around 45% of the current market. The growing pipeline of mRNA vaccines and therapeutics is creating sustained demand for lipid nanoparticle formulation and manufacturing capabil...

The global primary cells market, valued at USD 1.19 billion in 2025, is projected to reach USD 1.26 billion in 2026 and USD 2.04 billion by 2035, representing a CAGR of 5.5% during the forecast period 2026 to 2035. In terms of source of origin, cells sourced from humans hold the highest share (nearly 75%) of the current market. With respect to type of organ system, cells sourced from the nervous system dominate the current market. Based on the type of primary cells, fibroblasts account for the l...

The adeno associated virus vector manufacturing market, valued at USD 79 million in 2025, is projected to reach USD 93 million in 2026 and USD 325 million by 2035, representing a CAGR of 15% during the forecast period 2026 to 2035. In terms of type of manufacturer, the adeno-associated virus vector manufacturing market is dominated by contract manufacturers (58%) and this trend is unlikely to change in the coming years as well. In May 2026, Catalent collaborated with Elpida Therapeutics with an...

The global cultured meat market, valued at USD 0.27 billion in 2025, is projected to reach USD 0.34 billion in 2026 and USD 229 billion by 2050, representing a CAGR of 31% during the forecast period from 2026 to 2050. In recent years, there has been a perpetual rise in the global population. According to recent estimates provided by the United Nations, the world population is projected to reach 9.8 billion by 2050. This demographic trend is accompanied by an increase in demand for food, particu...

The global exoskeleton market, valued at USD 2.9 billion in 2025, is projected to reach USD 3.7 billion in 2026 and USD 20.3 billion by 2035, representing a CAGR of 20.8% during the forecast period 2026 to 2035. The exoskeleton market is gaining relevance as mobility impairment becomes a larger clinical, social, and economic burden. Neurological conditions are now among the leading causes of disability worldwide; in 2025, the World Health Organization reported that neurological conditions affect...

The global organs-on-chips market, valued at USD 100 million in 2025, is projected to reach USD 129 million in 2026 and USD 944 million by 2035, representing a CAGR of 24.8% during the forecast period 2026-2035. In terms of geographical regions, North America currently holds the highest share, accounting for ~45% of the overall market. In May 2026, Critical Path Institute launched the NAMs Developer Coalition, bringing together developers such as CN Bio, Curi Bio, Emulate, and InSphero to advanc...

The North America medical device contract manufacturing market, valued at USD 40.9 billion in 2025, is projected to reach USD 43.9 billion in 2026 and USD 75.5 billion by 2035, with a CAGR of 6.2% during the forecast period 2026 to 2035. North America represents the largest and most advanced market for medical device contract manufacturing, driven by its robust medtech ecosystem and strong culture of innovation. The US, in particular, continues to generate significant demand for contract manufac...

The Europe liquid biopsy market, valued at USD 2.0 billion in 2025, is projected to reach USD 2.3 billion in 2026 and USD 7.4 billion by 2035, representing a CAGR of 13.8% during the forecast period 2026 to 2035. Cancer diagnosis has traditionally relied on tissue biopsy, as it provides direct access to tumor material and helps clinicians understand the biological and molecular characteristics of the disease. However, the procedure is often associated with several practical and patient-related l...

The North America cancer metabolism based therapeutics market, valued at USD 1.32 billion in 2025, is projected to reach USD 1.78 billion in 2026 and USD 12.03 billion by 2035, with a CAGR of 23.7% during the forecast period 2026 to 2035. North America continues to report a substantial oncology disease burden, creating sustained demand for therapies that can address difficult-to-treat and genetically defined cancers. In the US alone, around 2.11 million new cancer cases and 626,140 cancer deaths...

The North America liquid biopsy market, valued at USD 4.5 billion in 2025, is projected to reach USD 5.2 billion in 2026 and USD 17.4 billion by 2035, representing a CAGR of 14.4% during the forecast period 2026 to 2035. Tissue biopsy has historically served as the standard approach for cancer diagnosis and molecular profiling, as it allows clinicians to directly examine tumor tissue and identify disease-specific characteristics. However, its invasive nature often creates challenges for patients...

The global RNAi therapeutics and technology market, valued at USD 6.2 billion in 2025, is projected to reach USD 7.4 billion in 2026 and USD 21.6 billion by 2035, representing a CAGR of 12.6% during the forecast period 2026 to 2035. In June 2026, Arrowhead Pharmaceuticals received European Commission marketing authorization for REDEMPLO® (plozasiran), a small interfering RNA medicine for adults with familial chylomicronemia syndrome. In June 2026, AviadoBio expanded its exclusive license for th...

The global rapid sterility testing for cell and gene therapies market, valued at USD 0.15 billion in 2025, is projected to reach USD 0.18 billion in 2026 and USD 0.80 billion by 2035, representing a CAGR of 18.0% during the forecast period from 2026 to 2035. The expanding clinical pipeline of advanced therapies has increased the demand for quality control methods that can deliver ultra-fast results. There is a prominent industry shift toward molecular diagnostics that utilize genetic targeting t...

The global ulcerative colitis market size, valued at USD 13.0 billion in 2025, is projected to reach USD 14.0 billion in 2026 and USD 25.7 billion by 2035, representing a CAGR of 7.0% during the forecast period 2026 to 2035. Based on route of administration, the subcutaneous route dominates (more than 40%) the current market; this trend is unlikely to change in the future. With respect to distribution channels, hospital pharmacies are expected to capture most of the future ulcerative colitis mar...